Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome.
Nonata
R
R
Laboratory of Dermatomycology, University of Brasilia, Brazil.
Sampaio
R
R
Marsden
P D
PD
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004337:Drug Carriers; D004351:Drug Resistance; D005500:Follow-Up Studies; D006801:Humans; D007897:Leishmaniasis, Mucocutaneous / Q000188:drug therapy*; D008081:Liposomes; D008297:Male; D008536:Meglumine / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000981:Antiprotozoal Agents; D004337:Drug Carriers; D008081:Liposomes; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000666:Amphotericin B